Welcome to the php ebenezer's messageboard
see bottom for more info


Hah (30/01/22 20:10:20)
    (note to self - you're welcome to peep)
    I haven't updated myself on this topic for at least five years. So here's some help


    Cefiderocol! Nice.

    "Meropenem-vaborbactam has recently demonstrated higher clinical cure rates versus best available therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE), as well as for HABP and VABP. The safety and tolerability of imipenem-relebactam and meropenem-vaborbactam has been reported in various phase I pharmacokinetic studies and phase II and III clinical trials. Both combinations appear to be well tolerated in healthy subjects and hospitalized patients, with few serious drug-related treatment-emergent adverse events reported to date. In conclusion, relebactam and vaborbactam serve to broaden the spectrum of imipenem and meropenem, respectively, against β-lactamase-producing Gram-negative bacilli. The exact roles for imipenem-relebactam and meropenem-vaborbactam will be defined by efficacy and safety data from further clinical trials."

back to main board expand thread
Name email
Enter your message here :
Ask for confirmation if modified Are you not a spammer?
Show allowed tags
Show me the last post since :
local time shift :

come again

messageboard's PHP script is a courtesy of Laurent

 This board has been visited 215922 timesCurrent time is 02/07/22 08:44:43